Tag: multiparametric MRI

Benjamin Franklin is quoted as saying nothing can be said to be certain except death and taxes. Perhaps he didn’t include aging because a) at the time of his death in 1790 the average male life expectancy was 38, or b) he led a rich and vigorous life almost till his death at age 84 keep reading

For the right prostate cancer (PCa) patient, Active Surveillance (AS) is a good thing. Urologic professionals now see eye-to-eye on monitoring with a focus on “preventing overtreatment in patients for whom the benefit of treatment deferral outweighs the need for immediate oncologic control.”[i] That’s a technical way of saying, if you don’t have clinically significant keep reading

Prostate cancer (PCa) is considered an aging-related disease. The older a man becomes, the more likely he will develop it. It is the most common cancer in older men.[i] The Prostate Cancer Foundation says, “Although only about 1 in 456 men under age 50 will be diagnosed, the rate shoots up to 1 in 54 keep reading

“I can’t afford it.” Unless you’re an impulse buyer, no matter how attractive a purchase looks you’re going to take the cost into account. Will your budget accommodate your desire? Of course, there strategies that can bring you closer to getting what you want. For example, you can: Shop around and compare prices for the keep reading

At the Sperling Prostate Center we strive to stay abreast of published studies in our field of prostate MRI. There are so many areas to stay on top of. To name just a few: Advances in MRI parameters like Diffusion Weighted Imaging or Dynamic Contrast Enhanced Comparing in-bore MRI guidance vs. fusion guidance for prostate keep reading

Why has it taken so long for someone to denounce the digital rectal exam (DRE) as a screening tool? Despite expert opinion against the DRE, many primary care doctors still do a DRE as part of routine annual checkups. The DRE has also been considered an essential monitoring practice for prostate cancer (PCa) patients on keep reading

The most common type of prostate cancer (PCa), acinar adenocarcinoma, normally starts in the gland cells that line the prostate and make prostate fluid. If diagnosed at an early stage when it’s still localized, it can almost always be conquered. It wasn’t that long ago when treatment was designed to clobber the entire gland. This keep reading

It’s hard to imagine the imagination of science fiction writers. While many of their literary works are based in our current world, like Michael Crichton’s novel The Andromeda Strain, science fiction works are not bound by past, present or future. In fact, the majority envision scientific or technological advances that don’t yet exist. As a keep reading

As Artificial Intelligence (AI) has boomed with countless applications in virtually every field of technology and learning, medicine is also benefitting. A branch of AI called Deep Learning (DL) is modeled after the layers of neural networks involved in the brain’s learning processes. By layering algorithms, to process data, DL mimics how the brain thinks, keep reading

If you’ve been diagnosed with low-risk prostate cancer, chances are your doctor has said you may be a candidate for Active Surveillance (AS). The National Cancer Institute defines AS as a cancer management strategy to avoid or delay treatments with side effect risks. It “involves closely watching a patient’s condition but not giving any treatment keep reading